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Cancer treatments can be damaging to the ovary, with implications for future fertility and
reproductive lifespan. There is therefore a need for a biomarker than can usefully provide
an assessment of the ovary and its potential for long-term function after cancer treatment,
and ideally also be of value pre-treatment, for the prediction of post-treatment function. In
this review we assess the value of anti-Müllerian hormone (AMH) in this context.
Measurement of AMH at the time of cancer diagnosis has been shown to be predictive
of whether or not there will remain some ovarian function post-treatment in women with
breast cancer, in conjunction with age. AMH may however be reduced at the time of
diagnosis in some conditions, including lymphoma, but probably not in women with breast
cancer unless they are carriers of BRCA1 mutations. Following chemotherapy, AMH is
often much reduced compared to pretreatment levels, with recovery dependent on the
chemotherapy regimen administered, the woman’s age, and her pretreatment AMH.
Recent data show there may be a long duration of relative stability of AMH levels over 10 to
15 years prior to decline rather than a rapid decline for many young women after cancer.
Post-treatment AMH may have utility in determining that ovarian function will not recover,
contributing to assessment of the need for ovarian suppression in women with hormone-
sensitive breast cancer. AMH measurement provides an index of treatment
gonadotoxicity, allowing comparison of different treatment regimens, although
extrapolation to effects on fertility requires caution, and there are very limited data
regarding the use of AMH to estimate time to menopause in the post-cancer setting.
Keywords: ovarian reserve, cancer, anti-Müllerian hormone, fertility preservation, premature ovarian insufficiencyINTRODUCTION
Adolescent and young adult cancer survivors can experience many late effects related to their cancer
treatment. With substantial improvements in survival following many common cancers, perhaps
most importantly in the present context for women with breast cancer (1), and recognition of the
importance of quality of life following treatment, identifying, and treating reproductive and sexual
health late effects has become increasingly important for these young women. While not all cancer
treatments adversely impact the ovary, the overall likelihood of a woman having a pregnancy
following cancer treatment is reduced by nearly 40% across all diagnoses (2). Cancer survivorsn.org October 2020 | Volume 11 | Article 5742631
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individualized risks of adverse sexual and reproductive health
outcomes and clinical management options, contributing to
lower quality of life and distress (3, 4).
Ovarian function, specifically the development of ovarian
follicles and associated reproductive hormones, contributes
directly to reproductive and sexual health in this population.
Measures of ovarian function for diagnostic and predictive
indications may help clinicians and patients understand their
current as well as predicted future ovarian function. While
conventional indicators of ovarian function, namely cyclical
menstruation, gonadotropins, estradiol, and progesterone
remain essential for assessing current ovarian function (growth
of larger follicles and ovulation), the last 15 years have seen a
substantial interest in the potential value of measuring anti-
Müllerian hormone (AMH). The objective of this review is to
discuss current understanding of the clinical value of measuring
AMH in young cancer survivors at cancer diagnosis and post-
treatment. Specific questions we address include whether AMH
levels at cancer diagnosis and/or post-treatment predict response
to ovarian stimulation in the short-term, and fertility or time to
menopause in the long-term. We also discuss how AMH levels
reflect current ovarian function and help to estimate the
gonadotoxicity of cancer treatments.
Other reviews in this collection will address many of the
details surrounding the origins of AMH and what is known
about its role and value in normal ovarian physiology. For the
present context, the key points are that AMH is not produced by
primordial follicles, but it is produced by the granulosa cells of
growing preantral and small antral follicles. There is a
relationship between the number of primordial follicles and the
number of growing follicles in the adult human ovary (5), and
the limited data available show that AMH levels correlate with
the number of primordial follicles (6). Thus, AMH is an indirect
marker of the true ovarian reserve, i.e., the number of non-
renewable, non-growing primordial follicles. Importantly, AMH
production by granulosa cells falls dramatically when follicles
reach a diameter of approximately 10 mm, and it is estimated
that follicles of 5 to 8 mm diameter contributes the majority of
circulating AMH (7). These follicles will have been in the growth
phase for a significant period of time, probably many weeks, and
are approaching a key timepoint when they may or may not be
selected for dominance and ovulation, with the great majority, as
at all stages of follicle growth, destined for atresia. Thus, AMH
may be regarded as a reflection of what can be termed the
functional ovarian reserve, which is those follicles which are
starting to produce estrogen and in contributing to basal, early
follicular, estrogen production, and underpinning the potential
for ovulation. This is, of course, the basis for the value of AMH-
based treatment strategies in assisted reproduction, as an index
of follicular response to ovarian stimulation.
A further important attribute of AMH is that is it detectable
in the circulation in childhood as well as in adults, though with
complex age-dependent changes (8, 9). Specifically, after a
temporary neonatal peak, AMH levels are initially low in
childhood, rising to a plateau after puberty until the mid 20s,Frontiers in Endocrinology | www.frontiersin.org 2then progressively decline thereafter to undetectable levels
associated with the menopause. It is important to recognize
that these physiological changes in AMH levels may result in a
peri-pubertal decline and then rise in adolescent girls, which
complicates interpretation during puberty and the years
thereafter. While the relationship between AMH and the
ovarian reserve thus changes between childhood, adolescence
and early adulthood, and the main reproductive years (10), the
measurement of AMH allows some assessment of ovarian
function in prepubertal girls as well as young adults.MEASURING AMH BEFORE CANCER
TREATMENT
The measurement of AMH at the time of diagnosis in women
with cancer has two important clinical uses. Typically measured
in clinics, most immediately, it is of value in assessing the
functional ovarian reserve in women considering ovarian
stimulation for fertility for egg or embryo vitrification for
fertility preservation, and therefore the question is whether it
has the same predictive value as in the normal situation in
women having assisted reproduction. Second, in conjunction
with age and cancer treatment, it may be of value in predicting
long-term ovarian function after cancer treatment is completed.
AMH and Ovarian Stimulation for Fertility
Preservation Before Cancer Treatment
Data showing that AMH levels are reduced in women with
lymphoma at the time of diagnosis compared to age match
controls (11, 12). This may reflect the systemic inflammatory
nature of lymphoma compared to other cancers, as AMH levels
do not appear to be reduced in women with breast cancer (13, 14).
Higher AMHpredicts higher oocyte yield in ovarian stimulation of
cancer patients (15).Overall, the results of ovarian stimulationwith
regard to number of oocytes retrieved and proportion fertilized are
similar inwomenwith cancer towomenwithout cancer (16). There
is, however, evidenceof reducedoocyte quality compared towomen
cryopreserving oocytes for elective purposes (17), which is not
reflected by AMH.
AMH in Women With BRCA Mutations
A special situation in the context of breast cancer is the potential
impact of mutations in the BRCA1 and BRCA2 genes on ovarian
function. These genes encode proteins involved in the DNA
damage repair pathway, which is of key importance in the oocyte
(18), and there is good evidence from animal models that BRCA1
in particular is necessary for normal fertility and ovarian lifespan
(19). That study also suggested that women with BRCA1
mutations also had lower AMH levels, and a reduced response
to ovarian stimulation, and BRCA1/2 carriage has been linked
with an earlier age at natural menopause (20). It appears that
women with BRCA1 mutations, but probably not those with
BRCA2 mutations, do have a lower AMH level overall; it was
found to be 25% lower in a study including 172 BRCA1mutationOctober 2020 | Volume 11 | Article 574263
Anderson and Su AMH Women In Cancercarriers (21), who were also more likely to have AMH levels in
the lowest quartile (odds ratio 1.84, 95% CI: 1.11–303).
Comparably, a reduced response to ovarian stimulation has
also been reported in a cohort of BRCA1 mutation carriers,
with no effect in BRCA2 mutation carriers (22). Others have
found that AMH levels are not reduced in BRCA mutation
carriers (23, 24), but those studies did not separately analyze
BRCA1 and BRCA2 carriers.
AMH at Cancer Diagnosis and Prediction
of Long-Term Ovarian Function
The value of AMH measurement at the time of diagnosis in
predicting long term ovarian function has been clearly
demonstrated in women with breast cancer, with limited data
for women with other diagnoses. Studies require a long-term
prospective cohort recruited at the time of diagnosis, and are
therefore relatively few in number. In women with breast cancer,
pretreatment AMH predicts long term ovarian function
measured as ongoing menses or not. In the first such analysis
AMH was shown to have a better predictive value than age (25,
26), although the latter is also, of course, an important predictive
factor. In a second similar prospective cohort, it was shown that
pretreatment AMH below the median value for the group, 0.46
ng/ml, accurately predicted amenorrhea in all women at 2 years
following diagnosis (27). Combining these two cohorts allowed
production of a mosaic chart showing the interaction between
age and AMH and pretreatment AMH in predicting whether or
not the woman was likely to have long term amenorrhea at—2 to
5 years after diagnosis (Figure 1). Subsequently larger cohorts
followed prospectively from diagnosis within breast cancer
treatment trials (28) and specifically recruited have produced
confirmatory data (29–31). In survivors of cancers other than
breast cancer, it has been shown that pretreatment AMH impacts
on the rate of recovery of AMH after chemotherapy, with higher
pretreatment AMH associated with more rapid recovery (32).
Importantly, the menstrual and AMH outcomes of these studies
are limited in part by heterogeneity of definition on duration and
timing after treatment, but indicate ovarian function and
estrogen production, important to sexual and bone health. To
date, however, no studies have investigated how pre-treatment
AMH levels are related to post-treatment fertility or time to
menopause in women with preserved ovarian function after
cancer treatment.MEASURING AMH AFTER
CANCER TREATMENT
AMH Is a Measure of Current Ovarian
Function in Post-Treatment
Cancer Survivors
It is recognized that recovery of ovarian function after
chemotherapy (as reflected in resumption of menses) varies by
age and by diagnosis/treatment (33, 34). Younger women show a
more rapid recovery, as do those treated for lymphoma
compared to breast cancer, and recovery can take 2 years, orFrontiers in Endocrinology | www.frontiersin.org 3occasionally longer. AMH levels show this recovery. When
modeling AMH in cancer survivors, levels are initially low
immediately post-treatment then rise to peak between 2 and 3
years later (35). Prospective studies in women with breast cancer
(median age 41), as discussed above, show both a marked fall
versus pretreatment levels and minimal recovery of AMH levels
over several years thereafter (25), while a comparable study in
younger women with lymphoma (mean age 24) showed a clear
divergence of the pattern of AMH levels by different
chemotherapy regimens, with robust recovery of AMH levels
in women treated with ABVD versus very limited recovery in
women treated with high doses of alkylating agents (36).
With AMH levels drawn post-treatment as a reflection of
current ovarian function in those patients, age, AMH at the end
of treatment, and BMI are factors associated with the rate and
extent of recovery in AMH following treatment. In addition to
younger age, having a higher AMH at the end of treatment is
associated with greater and faster recovery (32), and higher BMI
may also be related to shorter time to recovery (31).
Following recovery after cancer treatment, AMH will again
decline as it does in all women. Although this is a challenging
aspect of the subject to study, whether the rate of decline is
affected by prior chemotherapy has been investigated. In anFIGURE 1 | Classification mosaic chart for ongoing menses (M) or
chemotherapy-related amenorrhea (A) at 2 to 5 years after diagnosis using
serum AMH and chronological age at cancer diagnosis as predictor variables.
The primary cutoff values are both for AMH, with below 3.8 pmol/L predicting
amenorrhea and above 20.3 pmol/L predicting ongoing menses. Between
these AMH levels there is an age threshold at 38.6 years, above which
amenorrhea is predicted and below which ongoing menses are predicted.
The classification schema has sensitivity 98·.2% (1 of 55 subjects known to
have developed amenorrhea misclassified as having ongoing menses) and
specificity 80.0% (4 of 20 subjects with known ongoing menses misclassified
as amenorrhoeic). After 10-fold cross-validation this schema represents the
optimal compromise between good fit to the data used to construct it, and
low estimated error when used as a predictive model. Reprinted from (27)
with permission.October 2020 | Volume 11 | Article 574263
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aged 15 to 39 years over a 2-year period, the rate of decline in
AMH was similar to that in similarly aged controls, albeit at
lower levels overall, and in both younger groups was much
slower than in older women, aged 40 to 50 years (37). A
second study reported the slope of change in AMH over
approximately 3 years in long-term childhood cancer survivors
(median of 16 years since cancer treatment) was similar to
women without cancer (38). Taken together, although AMH
levels will on average be lower in a cancer survivor than a woman
without cancer, there may be a long duration of relative stability
with a plateau over 10 to 15 years prior to decline rather than a
rapid decline for many young women who are cancer survivors
(35). This is very reassuring for such patients, although
additional detail is needed to confirm that this applies across
the range of AMH levels.
The Relationship Between Cancer
Treatment and Ovarian Function is
Reflected by AMH, and Is Modified by Age
In a recent analysis of recovery of ovarian function following
treatment for Hodgkin lymphoma, it was confirmed that women
treated with ABVD overall showed a complete recovery of AMH
levels, in contrast to those treated with BEACOPP (Figure 2)
(39). However, within the ABVD treated group recovery of AMH
levels was markedly reduced to approximately 35% of
pretreatment values in women aged over 35, whereas it was
complete in younger women. This was not related toFrontiers in Endocrinology | www.frontiersin.org 4pretreatment AMH levels, thus young women with a low AMH at
diagnosis showed a good recovery whereas older women with a
higher AMH did not, thus the effects of age may be indicative of
other aspects of ovarian aging, perhaps affecting the stroma or
vasculature, and their damage by chemotherapy (40). The effect of
age on recovery of ovarian function was also demonstrated in FSH
levels,whichwere slower toreturn tonormal inwomenagedover35
than in younger women (39). This differential relationship between
chemotherapy and post-treatment AMH levels by age in women
with Hodgkin lymphoma is in contrast to data in women with
breast cancer, where no effect modification has been observed.
Potential explanations include the overall older age of the breast
cancerpopulation,with themajority in their late30s andearly40s in
most studies, or it may reflect the gonadotoxicity of chemotherapy
with overall much less recovery of AMH in women treated with
breast cancer chemotherapy regimens.
Indeed, age modified the relationship between gonadotoxicity
and post-treatment AMH trajectories in a large cancer survivor
cohort (35). The trajectory for high gonadotoxicity (high dose
alkylators, pelvic radiation, transplant) had a noticeably steeper
decline after its initial rise in the first 2 to 3 years since cancer
treatment, compared to the trajectories of the moderate and low
gonadotoxicity groups which showed a prolonged plateau. In the
same cohort, survivors who were older than age 30 at diagnosis
exhibited consistently lower AMH trajectories compared to those
younger than 25 years and those between ages 25 and 30 years. A
test of interaction between age at treatment and gonadotoxicity
was statistically significant, and data suggested that the protective
effects of younger age on ovarian reserve when exposed to high
gonadotoxicity treatments becomes diminished in the latter 20s.
Importantly, in the present context, recovery of AMH after
chemotherapy does not reflect an increase in the ovarian reserve,
but a recovery in the population of growing (AMH-producing)
follicles in the functional ovarian reserve. Similarly AMH levels
are reduced in healthy women taking hormonal contraception
(41), and are also reduced in women with some cancer diagnoses,
before treatment as discussed above.
Acute and Long-Term AMH Levels
as Measures of Cancer
Treatment Gonadotoxicity
Many cross-sectional studies clearly show that treatment type is
related to AMH levels, both acutely and over the long-term. The
first such study to show this was in young women who had been
treated for childhood cancer, but who still had regular menstrual
cycles thus overtly had normal ovarian function (42). These
women were shown to have reduced AMH levels compared to
age match controls and this key finding of the added value of
AMH in assessment of post-treatment ovarian reserve has
subsequently been replicated in a large number of studies
across a range of diagnoses. Subsequent studies showed that
AMH was markedly low following treatment for breast cancer
(43, 44), following alkylating agent therapy and treatments
associated with bone marrow transplantation (45), in women
treated for Hodgkin lymphoma in childhood where a
relationship with dose of alkylating agent was identified (46),
and across a range of diagnoses in childhood and young adultFIGURE 2 | AMH concentrations at pre-chemotherapy, after two cycles of
ABVD, at end of treatment and at 1, 2, and 3 years after chemotherapy. Blue:
women treated with ABVD throughout; red, women treated with BEACOPP
after two cycles of ABVD. Boxes are median and IQR, whiskers indicate
range. AMH is plotted on a log10 scale to show the low concentrations
during and after BEACOPP more clearly. Numbers of subjects at each time
point indicated below. Reprinted from (39) with permission.October 2020 | Volume 11 | Article 574263
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alkylating agent and pelvic radiotherapy. The limitation of cross-
sectional studies is that they shed little light on the pattern of
change of ovarian function post treatment.
More limited prospective data are available. In a pediatric
cohort of 22 girls with a range of diagnoses and aged 0.3 to 14
years, AMH fell progressively with each course of chemotherapy
becoming undetectable in approximately half the group (51). The
key finding was that initial fall of AMH levels and recovery varied
by treatment regimen, with those treated with regimens assessed
as having low/moderate gonadotoxicity showing recovery to
pretreatment AMH levels, whereas those treated with high risk
regimens (containing high doses of alkylating agents, or with
pelvic radiotherapy) showed lower levels at the end of treatment
and minimal or no recovery. Inhibin B and FSH were of no value
in discriminating these treatment effects. This may allow
improved assessment of girls at pre- and peri-pubertal ages,
and support timely treatment for induction of puberty where
there is clear and early evidence of absent ovarian function.
Variation in AMH levels by treatment also suggest that AMH
may serve as a biomarker of gonadotoxicity. Acutely, between
cancer diagnosis and end of treatment, AMH levels fell more in
those exposed to alkylating chemotherapy exposure, compared
to those not exposed to alkylators (32). Longitudinally, the rate of
recovery in AMH did not vary by alkylator exposure, but this
could be limited by sample size. Recently, using a hybrid cross-
sectional and prospective cohort design, the post-treatment
trajectory of AMH was modeled based on data from 763
patients with common cancers (Figure 3) (35). The magnitude
of AMH recovery and duration of plateau was less for those
whom underwent highly gonadotoxic therapies, compared to
low or moderate gonadotoxic treatment groups. This study also
used AMHmeasurements in dried blood spots collected at home:
this technique may be of value to pursue large-scale clinically
important questions.
Post-Treatment AMH and Diagnosing
Ovarian Insufficiency
The accurate diagnosis of permanent ovarian insufficiency is of
considerable value in patients treated for cancer beyond fertility
considerations. Ovarian function is also of importance in
hormone dependent breast cancer as it may impact on choice
of endocrine therapy. The use of aromatase inhibitors is now
established to improve survival in post-menopausal women with
breast cancer (52), but these drugs require concurrent ovarian
suppression with GnRH agonists in pre-menopausal women.
Uncertainty in identifying which women have become truly
post-menopausal following treatment when they were pre-
menopausal beforehand results in reluctance to stop GnRH
agonist ovarian suppression even when in reality in an
individual patient it may not be required. In the context of the
normal menopause, initial studies showed that AMH became
undetectable several years before the menopause, and therefore
the assays available at that time were clearly insufficiently
sensitive to have confidence in the use of AMH as an accurate
diagnosis of POI following chemotherapy. However, currentlyFrontiers in Endocrinology | www.frontiersin.org 5available assays, both automated (Roche and Beckman Coulter)
and the manual PICO assay (Ansh laboratories), have markedly
improved sensitivity, and data on the relationship between AMH
and natural menopause are becoming clearer (53), although age
remains an important determinant of the accuracy of prediction.
In a re-analysis of 98 blood samples taken 2 years after breast
cancer treatment using the PICO assay, undetectable AMH was
an extremely good predictor that ovarian function would not
recover over the following few years, with 96% specificity (54).
Subsequently the value of an undetectable AMH level, using the
Roche automated assay, was shown to be an accurate diagnostic
test for POI at 2 years following diagnosis with 100% sensitivity
and 73% specificity (55), thus it appears that after allowing 2
years for any potential recovery of ovarian function, an
undetectable AMH level is indeed an accurate index that
recovery of ovarian function is very unlikely. While these data
are exciting, it is important to note that substantial inter-assay
differences remain with regard to AMH assays (56), which may
be of particular importance at the lower limit of detection, and
thus, the generalizability of cut points is assay-dependent. It is
also the case that a proportion of women, perhaps as high as 10%
in a young population (57), may have episodes of vaginal
bleeding after more than 2 years of post-cancer amenorrhea,
possibly reflecting transient ovarian activity.
AMH levels have been shown to be not influenced by
tamoxifen co-administration, but they are suppressed by
GnRH agonist administration over a period of several
months (25), thus that needs to be taken into account in
analyzing AMH levels in that context. Given the high
predictive value of an undetectable AMH level at 2 years, theFIGURE 3 | AMH trajectories in 718 post-treatment AYA cancer survivors
ages 25 to 40 years at AMH measurement. Data are divided into three
gonadotoxicity groups, predicted mean log-transformed AMH trajectories
over years since cancer treatment (bold lines with green for low, blue for
moderate, red for high gonadotoxicity). Mean curves are truncated when the
number of individual participants remaining in the group is fewer than 10.
Individual log-transformed AMH levels (+) and predicted trajectories (short
lines related to +) also are depicted in the same colour as their gonadotoxicity
group. This figure is original and based on data from (35).October 2020 | Volume 11 | Article 574263
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used to accurately identify permanent POI. In that same analysis
of women with breast cancer, AMH analysis at the end of
chemotherapy was also analyzed (55). Overall, in a group of 68
women, an undetectable AMH at end of chemotherapy had a
sensitivity of 78% and specificity of 82% for prediction of POI at
2 years, giving a diagnostic odds ratio of 10.9. This surpassed the
value of FSH, which while it had a very high sensitivity
(inevitable given that it is part of the diagnosis of POI), the
specificity was low, and the diagnostic odds ratio was only 5.5.
However, in a sub-group analysis of women aged over 40, the
accuracy of AMH at end of treatment was improved with a
sensitivity of 91% and specificity 82%, giving a high diagnostic
odds ratio of 42.8. It may therefore be that using these high
sensitivity assays that an AMH assessment on completion of
chemotherapy can accurately identify those women who will not
show any recovery of ovarian function following chemotherapy,
and this may be of value in determining the most appropriate
adjuvant endocrine treatment, but this may be limited to women
in their forties. More conservatively, breast cancer survivors who
are amenorrhoeic without GnRH agonist suppression for 2 years
after chemotherapy and have an undetectable AMH level may be
candidates for aromatase inhibitor endocrine therapy without
concurrent GnRH agonist, but subsequent vaginal bleeding
would require reassessment of ovarian function. This requires
prospective evaluation.CONCLUSION
The above discussion clearly shows the value of pre- and post-
treatment AMH in female cancer survivors for predicting post-
treatment ovarian function, serving as a biomarker of treatment
gonadotoxicity, and in the diagnosis of ovarian insufficiency,
particularly when a sufficient time for early recovery of ovarian
function has been allowed to elapse. Pretreatment analysis of
AMH level is of value in predicting long term ovarian function inFrontiers in Endocrinology | www.frontiersin.org 6women with breast cancer but its value in other diagnoses and
with other types of chemotherapy regimen, particularly when
less gonadotoxic are unclear. The interaction with age in this
respect is intriguing, and it is likely to require a greater
understanding of these adverse effects of chemotherapy on the
different compartments and cell types of the ovary. There are
promising data that in certain sub-groups AMH may be of value
shortly after completion of chemotherapy and ultimately this
may be of value in guiding adjuvant endocrine therapy in some
women with breast cancer. Current data suggest that AMH is not
of value in predicting short term fertility in women following
cancer treatment as shown both by specific analysis (58) and in
individual cases within larger analyses (39), as is the case for
women in the general population (59, 60). Unfortunately there
remains a dearth of data regarding the use of AMH to estimate
time to menopause in the post-cancer treatment setting and
beyond that into whether AMH can help stage the process of
reproductive senescence similar to in the general population
(61). Data are lacking on AMH’s relationship to non-
reproductive late effects relating to estrogen deficiency such as
bone health and potentially cardiovascular and cerebral vascular
function. Larger prospective studies with these diverse end points
are needed to clarify the key areas where AMH is of value in
this context.AUTHOR CONTRIBUTIONS
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